Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

News

Article

October 9, 2024

Brukinsa Recommended Versus Imbruvica in R/R CLL, SLL

Author(s):

Ashley Chan

Fact checked by:

Alex Biese

Key Takeaways

  • Brukinsa demonstrated superior efficacy and cardiac safety over Imbruvica in CLL/SLL treatment, especially in high-risk patients with 17p deletions.
  • The ALPINE phase 3 trial showed sustained progression-free survival and higher overall response rates with Brukinsa.
  • Common side effects included neutropenia, anemia, and COVID-19-related infections, with Brukinsa showing reduced cardiac side effects.
  • General lifestyle recommendations for managing side effects include proper diet, sleep, stress management, and exercise.
SHOW MORE

Patients with relapsed or refractory CLL or SLL may benefit from receiving Brukinsa instead of Imbruvica, as Brukinsa demonstrated superior effectiveness.

Illustration of cells.

Brukinsa demonstrated superior effectiveness compared to Imbruvica in treating relapsed or refractory CLL/SLL.

Treatment with BTK inhibitor Brukinsa (zanubrutinib) demonstrated superior effectiveness compared with BTK inhibitor Imbruvica (ibrutinib) in patients with relapsed (disease worsening after a period of improvement) or refractory (resistant to treatment) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a study.

A BTK inhibitor is a type of drug that blocks the activity of the Bruton tyrosine kinase protein, which is key in the development of B cells. These cells are a type of white blood cells that make antibodies, a special type of protein. The drug binds to BTK proteins to potentially stop the growth of cancer cells, according to the National Cancer Institute.

Before BTK inhibitors like Brukinsa and Imbruvica, patients with CLL or SLL received chemotherapy. However, “for some time now, BTK inhibitors like [Brukinsa] and [Imbruvica] have come into play. Patients can also get venetoclax-based therapy,” explained study author Dr. Jennifer R. Brown in an email interview with CURE®.

Brown is a medical oncologist and director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and the Worthington and Margaret Collette Professor of Medicine at Harvard Medical School, both in Boston.

Of note, a study published in the journal Blood demonstrated that patients who received Brukinsa had more favorable cardiac (heart) safety and tolerability versus Imbruvica. Because of the superior effectiveness of Brukinsa versus Imbruvica for longer than three years, the researchers emphasized that “we felt it was not in the best interest of patients to continue [Imbruvica].”

“As such, a decision was made to close the [ALPINE] study and allow eligible patients, including those originally assigned to [Imbruvica], to enroll in LTE-1,” the researchers wrote.

ALPINE was a phase 3 trial that included 652 patients who were randomly assigned to two groups: Brukinsa or Imbruvica. There were 327 patients in the Brukinsa group and 325 patients in the Imbruvica group, the researchers noted. In the Brukinsa and Imbruvica groups, the median follow-ups were 43.4 months and 41.6 months, respectively.

At an overall median follow-up of 42.5 months, the progression-free survival (PFS; time patients live without experiencing disease worsening or spreading) benefit was sustained in patients who received Brukinsa versus Imbruvica.

“I think one of the most interesting findings is that the benefit of [Brukinsa] is even greater in the highest risk subgroup of patients, those with 17p deletions,” Brown said.

Regarding the overall response rate (ORR; percentage of patients whose tumors shrunk or disappeared after treatment), patients treated with Brukinsa had a higher ORR at the overall follow-up of 42.5 months. The rate of partial responses with lymphocytosis (increase in lymphocytes, a type of infection-fighting white blood cell) or better was 90.2% compared with 82.8% in patients receiving Brukinsa and Imbruvica, respectively.

Side Effects Associated With Brukinsa and Imbruvica

The majority of side effects year after year remained stable, the study stated. Common changes included changes in neutropenia (lower levels of neutrophils, a type of white blood cell) and anemia reported in patients over time.

The majority of COVID-19-related infections were also reported between 24 and 36 months, according to the study. Reported deaths related to COVID-19 infection included 21 in the Brukinsa group and 22 in the Imbruvica group.

Other common treatment-emergent non-blood-related side effects in the Brukinsa and Imbruvica groups included upper respiratory tract infection, diarrhea and hypertension. Neutropenia was the most common blood-related side effect of any severity, the researchers explained.

“[Brukinsa] is a great treatment option, very well tolerated and highly effective. [Brukinsa] showed much reduced cardiac side effects compared to [Imbruvica] — this is something patients are often worried about,” Brown said.

Reference

"Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE" by Dr. Jennifer R. Brown, et al., Blood.

In terms of ways patients can help manage their side effects, Brown noted thatthere is “not that much, just the usual: eat right, get enough sleep, manage stress and exercise.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with brown hair.
‘The Future Is Bright’ for R/R CLL Treatment Landscape
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Focusing Research on T-Cell ALL to Further Treatment Options
Image of a man wearing a black button-up shirt.
Understanding Treatment Sequences in Managing R/R CLL
The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration
The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration
Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors
Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors
Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making
CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making
LL Treatment Roadmap: Navigating First-Line Options With Your Doctor
LL Treatment Roadmap: Navigating First-Line Options With Your Doctor
Watchful Waiting in CLL: When Waiting Is Treating
Watchful Waiting in CLL: When Waiting Is Treating
Connections: CLL Diagnosis: A Patient’s Perspective and Physician Insights
Connections: CLL Diagnosis: A Patient’s Perspective and Physician Insights
Related Content
Advertisement
Image of hands.
May 21st 2025

Sixteen Years With Leukemia Taught Me to Savor Life

Michelle Lawrence
I’ve lived with large granular lymphocytic leukemia for 16 years and have learned to spend my energy wisely, embrace palliative care and choose joy over anger.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Chester Freeman was diagnosed with bladder cancer and most recently with chronic lymphocytic leukemia (CLL). Read more of Chester's blogs here!
May 15th 2025

Finding Comfort in Teddy Bears Throughout My Experience With CLL

Chester Freeman
As a patient with CLL, I’ve found comfort in teddy bears — first as a chaplain offering solace, now as a patient embracing their quiet presence myself.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be recommended: © stock.adobe.com
April 21st 2025

Pausing BTKi for Vaccine Did Not Boost Immunity in CLL

Spencer Feldman
Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be recommended, a trial found.
After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers: © stock.adobe.com.
April 20th 2025

“Chillin’ Out” and Finding Our Cancer Community

Andrew Schorr Esther Schorr
After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers.
Related Content
CLLLeukemia
CLL
|
Leukemia
Advertisement
Image of hands.
May 21st 2025

Sixteen Years With Leukemia Taught Me to Savor Life

Michelle Lawrence
I’ve lived with large granular lymphocytic leukemia for 16 years and have learned to spend my energy wisely, embrace palliative care and choose joy over anger.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Chester Freeman was diagnosed with bladder cancer and most recently with chronic lymphocytic leukemia (CLL). Read more of Chester's blogs here!
May 15th 2025

Finding Comfort in Teddy Bears Throughout My Experience With CLL

Chester Freeman
As a patient with CLL, I’ve found comfort in teddy bears — first as a chaplain offering solace, now as a patient embracing their quiet presence myself.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be recommended: © stock.adobe.com
April 21st 2025

Pausing BTKi for Vaccine Did Not Boost Immunity in CLL

Spencer Feldman
Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be recommended, a trial found.
After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers: © stock.adobe.com.
April 20th 2025

“Chillin’ Out” and Finding Our Cancer Community

Andrew Schorr Esther Schorr
After nearly 30 years with cancer — community, research and education have helped us find hope, strength and purpose in the face of chronic blood cancers.
Advertisement
Advertisement
Advertisement
x
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.